Raymond James Financial Services Advisors Inc. Takes Position in Haleon plc (NYSE:HLN)

Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Haleon plc (NYSE:HLNGet Rating) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 262,407 shares of the company’s stock, valued at approximately $1,598,000.

A number of other large investors have also made changes to their positions in HLN. New England Research & Management Inc. acquired a new position in shares of Haleon during the third quarter valued at about $181,000. Stonebridge Capital Management Inc. acquired a new position in shares of Haleon during the third quarter valued at about $68,000. DAVENPORT & Co LLC bought a new stake in Haleon in the third quarter valued at about $181,000. Jacobs & Co. CA bought a new stake in Haleon in the third quarter valued at about $1,027,000. Finally, Bonness Enterprises Inc. bought a new stake in Haleon in the third quarter valued at about $403,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Down 2.9 %

Shares of Haleon stock opened at $7.91 on Thursday. Haleon plc has a 1-year low of $5.59 and a 1-year high of $8.50. The business’s 50-day moving average price is $7.47.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Argus assumed coverage on shares of Haleon in a research note on Wednesday, September 28th. They issued a “hold” rating on the stock. Barclays raised shares of Haleon from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 7th. Finally, Morgan Stanley raised shares of Haleon from an “equal weight” rating to an “overweight” rating in a research note on Friday, January 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $298.00.

Haleon Profile

(Get Rating)

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.

Featured Articles

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.